Seres Therapeutics Stock News

Seres' $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market - how big is it? Who can compete with the Seres/Nestle (Aimmune

U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates

SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy.

Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection. This completes Seres package for BLA (Biologics License Application) to

Here's what you need to know about trading on June 8th The post What to Know About Buying Penny Stocks on June 8th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

Seres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI).

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President and Chief Executive

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Destiny Pharma's 29021 year-end cash of £4.65mln together with a £6.5mln fundraise in March 2022 provides a funding runway into mid-2023, says house broker finnCap. “With several companies active

During the last session, Seres Therapeutics Inc. (NASDAQ:MCRB)’s traded shares were 0.83 million, with the beta value of the company hitting 3.41. At the end of the trading day, the stock’s price was $7.12, reflecting an intraday loss of -4.43% or -$0.33. The 52-week high for the MCRB share is $25.06, that puts it down … After A 13.02% Jump In The Last Week, Does Seres Therapeutics Inc. (NASDAQ: MCRB) Still Make Sense To Buy? Read More »

Seres misses on earnings and revenue, although revenue was up 344% to $144.92 million.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will b